Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.
A prospective randomized trial testing regional hyperthermic perfusion with melphalan has been conducted. Sixty-nine patients with recurrent malignant melanoma of the extremities were randomly allocated to surgery (36 patients) or surgery plus regional perfusion (33 patients). Prognostic variables concerning primary tumor as well as the recurrent disease were evenly distributed in the groups, excluding any bias in the randomization. Median tumor-free survival after randomization was 17 months in the perfusion group and 10 months in the control group. There were 15 locoregional recurrences in the perfusion group and 24 in the control group. The tumor-free survival curve was significantly (P = .044) better for the perfusion group than for the control group. Median survival time after randomization was 57 months in the perfusion group and 35 months in the control group. This difference was not significant. One patient died within 1 month after perfusion of pulmonary embolism. Regional hyperthermic perfusion after surgery of recurrent malignant melanoma should only be recommended in prospective and controlled trials, until its value has been proven in several randomized studies.
Hafström
L
L
Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden.
Rudenstam
C M
CM
Blomquist
E
E
Ingvar
C
C
Jönsson
P E
PE
Lagerlöf
B
B
Lindholm
C
C
Ringborg
U
U
Westman
G
G
Ostrup
L
L
D000328:Adult; D000368:Aged; D001132:Arm; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects / Q000379:methods*; D007866:Leg; D008297:Male; D008545:Melanoma / Q000601:surgery / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate
D008558:Melphalan